What Happened?
Shares of healthcare tech company Omnicell (NASDAQ: OMCL) jumped 3.3% in the afternoon session after an analyst at Wells Fargo raised the firm's price target on the stock and maintained an "Overweight" rating.
The price target was increased to $40 from $37, with the analyst citing a more favorable outlook on tariffs. The firm noted that a recent U.S.-China deal suggests a significantly lower tariff rate on Chinese imports than previously expected, which could reduce the financial drag on Omnicell's 2025 results. Wells Fargo subsequently raised its 2025 adjusted EBITDA estimate for the medication management solutions provider.
After the initial pop the shares cooled down to $27.65, up 2.9% from previous close.
Is now the time to buy Omnicell? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Omnicell’s shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 10 days ago when the stock dropped 3.7% on the news that the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies.
The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses.
Omnicell is down 37.6% since the beginning of the year, and at $27.65 per share, it is trading 47.9% below its 52-week high of $53.05 from October 2024. Investors who bought $1,000 worth of Omnicell’s shares 5 years ago would now be looking at an investment worth $405.37.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
